Boston, MA 05/13/2014 (wallstreetpr) – Prothena Corporation PLC (NASDAQ:PRTA) is one of the leading companies of USA. The company recently announced the financial results of Q1. According to the news the EPS of the company was $0.78. Unfortunately it missed the consensus estimate of $0.81 by $0.03 points.
The company has got the different ratings from the analysts of top notched investment banks and rating agencies.
The rating team of Wedbush has upgraded the company from ‘neutral’ to ‘best idea list’. While one of the other investment company group Citigroup Inc. gave a rating of ‘buy’ to the company after going through the excellent results produced by the company over the past few months. In total one investment analyst has given ‘hold’ rating, and four analyst have given ‘buy’ rating to the company.
Prothena Corporation PLC (NASDAQ:PRTA) has done comparatively better in last some time. The total market cap of the company is $474.2 million. The first quarter of the current year was quite good for the company. The company had an average daily trading of 317,681 shares which was more than the previous months.
About the company:
Prothena Corporation is a leading biotechnology firm which focuses on clinical-stage activities. The company’s main focus is on development, discovery, and commercialization of the various antibodies which are directed towards those diseases which involve protein cell adhesion or mis-folding.
Though the global drug and health industry is not doing very good, but this company has stuck to the basics and as a result of that, the performance in the last few months has been phenomenal. The market conditions are improving day by day for the industry, so the management of Prothena Corporation PLC (NASDAQ:PRTA) can think of better financial figures in the coming few months. So far everything is going good, everything will be clear in the coming few months time.
